Beta Bionics, Inc. $BBNX Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its stake in Beta Bionics, Inc. (NASDAQ:BBNX) by 4,236.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 485,854 shares of the company’s stock after acquiring an additional 474,651 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Beta Bionics were worth $4,868,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Values First Advisors Inc. raised its position in shares of Beta Bionics by 35.1% during the 1st quarter. Values First Advisors Inc. now owns 47,551 shares of the company’s stock worth $476,000 after purchasing an additional 12,360 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after buying an additional 1,818 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Beta Bionics by 140.9% during the fourth quarter. Invesco Ltd. now owns 117,360 shares of the company’s stock valued at $3,576,000 after acquiring an additional 68,640 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Beta Bionics during the fourth quarter valued at approximately $1,340,000. Finally, Voloridge Investment Management LLC lifted its position in shares of Beta Bionics by 549.6% in the fourth quarter. Voloridge Investment Management LLC now owns 151,647 shares of the company’s stock valued at $4,621,000 after acquiring an additional 128,301 shares in the last quarter.

Insider Buying and Selling

In other Beta Bionics news, Director Christy Jones sold 2,811 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $14.00, for a total transaction of $39,354.00. Following the completion of the sale, the director owned 27,400 shares of the company’s stock, valued at $383,600. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Hopman sold 5,329 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $67,198.69. Following the sale, the insider directly owned 130,887 shares of the company’s stock, valued at $1,650,485.07. The trade was a 3.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 40,351 shares of company stock worth $553,961 over the last ninety days. 5.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on BBNX shares. Bank of America lowered their price target on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. Weiss Ratings lowered shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Truist Financial reduced their target price on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. The Goldman Sachs Group decreased their price target on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Finally, Stifel Nicolaus lowered their price target on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $19.70.

Beta Bionics Price Performance

NASDAQ BBNX opened at $16.76 on Monday. The business’s fifty day simple moving average is $12.54 and its 200-day simple moving average is $15.04. The firm has a market cap of $746.83 million, a PE ratio of -11.10 and a beta of 3.04. Beta Bionics, Inc. has a 52 week low of $8.80 and a 52 week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The firm had revenue of $27.63 million during the quarter. Research analysts expect that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.